Ozekibart's 52% Reduction in Risk Sparks 70% Jump Amid Concerns Over Liver Safety
- Inhibrx Biosciences’ ozekibart showed 52% reduced disease progression risk in chondrosarcoma, driving a 70% post-market stock surge. - Combination trials in colorectal and Ewing sarcoma showed 23%–64% response rates, suggesting broader oncology potential. - Hepatotoxicity concerns led to monitoring strategies, reducing adverse events to 11.8% in ozekibart group. - Company plans 2026 BLA submission; stock surged 63% pre-market after prior 10% decline.
Shares of Inhibrx Biosciences (NASDAQ:INBX) soared by more than 70% in after-hours trading on October 23, 2025, after the company announced encouraging Phase 2 trial data for its investigational cancer therapy ozekibart (INBRX-109) in chondrosarcoma, a rare and aggressive bone malignancy that currently lacks approved systemic treatments, as reported by an
Ozekibart’s safety profile was generally acceptable, though liver toxicity was identified as a significant issue. Early in the study, a fatal liver-related incident led to the adoption of risk mitigation strategies, including excluding patients with advanced liver dysfunction and closely monitoring liver function during the initial treatment cycles. These interventions reduced the rate of treatment-related liver side effects to 11.8% in the ozekibart group versus 4.5% in the placebo group, with most cases being mild or moderate in severity, as detailed in
In addition to chondrosarcoma,
The company intends to file a Biologics License Application (BLA) with the U.S. Food and Drug Administration in the second quarter of 2026, according to Investing.com. Comprehensive data from the ChonDRAgon study will be presented at the Connective Tissue Oncology Society Annual Meeting on November 14, 2025, as noted by Tokenist.
The market responded strongly to the announcement, with
Financially, Inhibrx has a market capitalization near $457 million and maintains strong liquidity, with a current ratio close to 5, according to
INBX shares have climbed 140% year-to-date, reflecting strong investor confidence, though some warn that commercial success will depend on overcoming regulatory challenges and proving long-term effectiveness. With no approved therapies for chondrosarcoma, ozekibart’s potential to be first to market has drawn parallels to other breakthrough drugs in specialized oncology fields, according to Stocktwits.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
XRP News Today: Investors Divided: XRP's $5 Buzz Compared to Ozak AI's 7,000% Growth Promise
- XRP gains traction as analysts predict $5 price targets via ETF-driven inflows, citing historical Bitcoin multipliers. - Ozak AI emerges as AI-focused crypto alternative, raising $4.54M in presale with 7,000% return potential via decentralized AI infrastructure. - Market splits between XRP's institutional appeal and Ozak AI's utility-driven innovation, highlighting crypto's shifting risk-reward dynamics. - Analysts note XRP's capped growth vs. Ozak AI's 50X-100X potential, emphasizing real-world AI appli
Between Breakthroughs and Turmoil: The Struggle for Safety and Longevity in Cryptocurrency
- Crypto sector faces structural challenges balancing innovation with security and sustainability amid rising threats and regulatory uncertainty. - Mutuum Finance advances dual-lending architecture and mtToken mechanics under Halborn audit to build defensible DeFi models. - Upbit's $36M hack and Tether's Uruguay exit highlight systemic vulnerabilities from cyberattacks and energy cost volatility. - Industry shifts toward sustainable yield models with automated collateral rules and revenue redistribution to
Trump’s Selection of Hassett as Fed Chair Challenges Central Bank Autonomy
- Trump's nomination of Kevin Hassett as potential Fed Chair gains traction, positioning him as the leading candidate to replace Jerome Powell in 2026. - Hassett, a pro-crypto economist with Coinbase ties and Trump-aligned regulatory views, could shift Fed policy toward aggressive rate cuts and crypto-friendly frameworks. - Market odds favor Hassett (52-55% on prediction platforms), though mixed investor reactions and Senate confirmation challenges highlight risks to Fed independence. - Critics warn of pol
Dogecoin News Update: Practical Use Drives Digitap's $2.1M Presale Amid Bearish Market, Not Just Hype
- Digitap ($TAP) secures $2.1M in presale amid crypto bear market, contrasting ADA and DOGE's struggles with technical issues and weak demand. - Its utility-driven model, including Visa integration and cross-border payments, addresses gaps in traditional finance with sub-1% fees and 150M+ merchant access. - 90% presale allocation and 133M $TAP sold at 76% discount highlight demand, driven by 120K+ wallets linked during Black Friday promotions. - Analysts project $TAP could rise to $0.45–$3 by 2030, citing
Trending news
MoreCrypto prices
More
